Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Correction: Tadalafil Augments Tumor-specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma.

Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, Saunders J, Levine M, Tang M, Neuner G, Richmon JD, Blanco R, Agrawal N, Koch WM, Marur S, Weed DT, Serafini P, Borrello I.

Clin Cancer Res. 2018 Dec 1;24(23):6100. doi: 10.1158/1078-0432.CCR-18-3298. No abstract available.

2.

FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.

Marur S, Singh H, Mishra-Kalyani P, Larkins E, Keegan P, Sridhara R, Blumenthal GM, Pazdur R.

Semin Oncol. 2018 Aug;45(4):220-225. doi: 10.1053/j.seminoncol.2018.08.007. Epub 2018 Oct 31. Review.

PMID:
30391014
3.

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.

Ferrarotto R, William WN Jr, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS.

Oral Oncol. 2018 Jul;82:83-90. doi: 10.1016/j.oraloncology.2018.05.014. Epub 2018 May 19.

PMID:
29909907
4.

Ticks and salt: an atypical case of neuroborreliosis.

Siddiqui N, St Peter DM, Marur S.

J Community Hosp Intern Med Perspect. 2017 Dec 14;7(6):358-362. doi: 10.1080/20009666.2017.1407209. eCollection 2017.

5.

Reply to A. Garden et al.

Marur S, Li S, Cmelak A, Burtness B.

J Clin Oncol. 2017 Jun 10;35(17):1970-1971. doi: 10.1200/JCO.2017.72.8279. Epub 2017 Apr 21. No abstract available.

PMID:
28430530
6.

Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials.

Marur S, Cmelak AJ, Burtness B.

J Clin Oncol. 2017 Jun 10;35(17):1968-1969. doi: 10.1200/JCO.2017.72.2918. Epub 2017 Apr 21. No abstract available.

PMID:
28430529
7.

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B.

J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.

8.

Corrigendum to "Cetuximab activity in dysplastic lesions of the upper aerodigestive tract" [Oral Oncol. 53 (2016) 60-66].

Khan Z, Epstein JB, Marur S, Boyd Gillespie M, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris RL, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, Tsottles N, Ozawa H, Chung CH, Califano JA.

Oral Oncol. 2016 Jun;57:e8. doi: 10.1016/j.oraloncology.2016.03.018. Epub 2016 Apr 13. No abstract available.

PMID:
27085635
9.

Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment.

Marur S, Forastiere AA.

Mayo Clin Proc. 2016 Mar;91(3):386-96. doi: 10.1016/j.mayocp.2015.12.017. Review.

PMID:
26944243
10.

A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.

Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J.

Oral Oncol. 2016 Feb;53:54-9. doi: 10.1016/j.oraloncology.2015.11.020. Epub 2015 Dec 17.

11.

Cetuximab activity in dysplastic lesions of the upper aerodigestive tract.

Khan Z, Epstein JB, Marur S, Gillespie MB, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris R, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, Tsottles N, Ozawa H, Chung C, Califano JA.

Oral Oncol. 2016 Feb;53:60-6. doi: 10.1016/j.oraloncology.2015.11.016. Epub 2015 Dec 10.

PMID:
26686755
12.

Unusual Paraneoplastic Presentation of Cholangiocarcinoma.

Opneja A, Mahajan S, Kapoor S, Marur S, Yang SH, Manno R.

Case Rep Med. 2015;2015:806835. doi: 10.1155/2015/806835. Epub 2015 Oct 1.

13.

Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.

Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, Saunders J, Levine M, Tang M, Neuner G, Richmon JD, Blanco R, Agrawal N, Koch WM, Marur S, Weed DT, Serafini P, Borrello I.

Clin Cancer Res. 2015 Jan 1;21(1):30-8. doi: 10.1158/1078-0432.CCR-14-1716. Erratum in: Clin Cancer Res. 2018 Dec 1;24(23):6100.

14.

Oropharyngeal squamous cell carcinoma treatment: current standards and future directions.

Marur S, Burtness B.

Curr Opin Oncol. 2014 May;26(3):252-8. doi: 10.1097/CCO.0000000000000072. Review.

15.

Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer.

Campian JL, Sarai G, Ye X, Marur S, Grossman SA.

Head Neck. 2014 Dec;36(12):1747-53. doi: 10.1002/hed.23535. Epub 2014 Apr 15.

16.

Validation of a clinical prediction scale for hospital-onset Clostridium difficile infection.

Chandra S, Thapa R, Marur S, Jani N.

J Clin Gastroenterol. 2014 May-Jun;48(5):419-22. doi: 10.1097/MCG.0000000000000012.

PMID:
24172178
17.

Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years.

Paidpally V, Tahari AK, Lam S, Alluri K, Marur S, Koch W, Wahl RL, Subramaniam RM.

J Nucl Med. 2013 Dec;54(12):2039-45. doi: 10.2967/jnumed.113.121285. Epub 2013 Oct 7.

18.

Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer.

Tsao A, Hui EP, Juergens R, Marur S, Huat TE, Cher GB, Hong RL, Hong WK, Chan AT.

Cancer Med. 2013 Jun;2(3):351-9. doi: 10.1002/cam4.79. Epub 2013 Apr 18.

19.

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.

Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SC.

Thyroid. 2014 Feb;24(2):232-40. doi: 10.1089/thy.2013.0078. Epub 2013 Sep 10.

PMID:
23721245
20.

A cohort study for derivation and validation of a clinical prediction scale for hospital-onset Clostridium difficile infection.

Chandra S, Latt N, Jariwala U, Palabindala V, Thapa R, Alamelumangapuram CB, Noel M, Marur S, Jani N.

Can J Gastroenterol. 2012 Dec;26(12):885-8.

21.

Comment on "epidermal growth factor receptor is essential for toll-like receptor 3 signaling".

Burtness B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ.

Sci Signal. 2012 Dec 11;5(254):lc5. doi: 10.1126/scisignal.2003734.

PMID:
23233526
22.

Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma.

Chan JY, Sanguineti G, Richmon JD, Marur S, Gourin CG, Koch W, Chung CH, Quon H, Bishop JA, Aygun N, Agrawal N.

Arch Otolaryngol Head Neck Surg. 2012 Nov;138(11):1040-6. doi: 10.1001/jamaoto.2013.607.

23.

Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer.

Sosa JA, Balkissoon J, Lu SP, Langecker P, Elisei R, Jarzab B, Bal CS, Marur S, Gramza A, Ondrey F.

Surgery. 2012 Dec;152(6):1078-87. doi: 10.1016/j.surg.2012.08.036. Review.

PMID:
23158178
24.

Volumetric change of human papillomavirus-related neck lymph nodes before, during, and shortly after intensity-modulated radiation therapy.

Sanguineti G, Ricchetti F, Wu B, Agrawal N, Gourin C, Agbahiwe H, Marur S, Clemente S, McNutt T, Forastiere A.

Head Neck. 2012 Nov;34(11):1640-7. doi: 10.1002/hed.21981. Epub 2012 Jan 20.

25.

Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.

Sanguineti G, Sormani MP, Marur S, Gunn GB, Rao N, Cianchetti M, Ricchetti F, McNutt T, Wu B, Forastiere A.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):235-42. doi: 10.1016/j.ijrobp.2011.06.2000. Epub 2011 Nov 19.

PMID:
22104358
26.

Multidisciplinary head and neck cancer clinic and adherence with speech pathology.

Starmer H, Sanguineti G, Marur S, Gourin CG.

Laryngoscope. 2011 Oct;121(10):2131-5. doi: 10.1002/lary.21746. Epub 2011 Aug 8.

PMID:
21826674
27.

Impact of surgeon and hospital volume on short-term outcomes and cost of oropharyngeal cancer surgical care.

Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow RE.

Laryngoscope. 2011 Apr;121(4):746-52. doi: 10.1002/lary.21456.

28.

Volume-based trends in surgical care of patients with oropharyngeal cancer.

Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow RE.

Laryngoscope. 2011 Apr;121(4):738-45. doi: 10.1002/lary.21457. Epub 2011 Mar 10.

PMID:
21394725
29.

Volumetric change of selected organs at risk during IMRT for oropharyngeal cancer.

Ricchetti F, Wu B, McNutt T, Wong J, Forastiere A, Marur S, Starmer H, Sanguineti G.

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):161-8. doi: 10.1016/j.ijrobp.2010.01.071. Epub 2010 Nov 19.

PMID:
21306971
30.

Impact of surgeon and hospital volume on short-term outcomes and cost of laryngeal cancer surgical care.

Gourin CG, Forastiere AA, Sanguineti G, Koch WM, Marur S, Bristow RE.

Laryngoscope. 2011 Jan;121(1):85-90. doi: 10.1002/lary.21348. Erratum in: Laryngoscope. 2011 Feb;121(2):457.

PMID:
21181983
31.

Volume-based trends in laryngeal cancer surgery.

Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow RE.

Laryngoscope. 2011 Jan;121(1):77-84. doi: 10.1002/lary.21393.

PMID:
21125633
32.

HPV-associated head and neck cancer: a virus-related cancer epidemic.

Marur S, D'Souza G, Westra WH, Forastiere AA.

Lancet Oncol. 2010 Aug;11(8):781-9. doi: 10.1016/S1470-2045(10)70017-6. Epub 2010 May 5. Review.

33.

Update on role of chemotherapy in head and neck squamous cell cancer.

Marur S, Forastiere AA.

Indian J Surg Oncol. 2010 Apr;1(2):85-95. doi: 10.1007/s13193-010-0021-y. Epub 2010 Nov 21.

34.

Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer.

Marur S, Forastiere AA.

Curr Opin Oncol. 2010 May;22(3):206-11. doi: 10.1097/CCO.0b013e328338475c. Review.

PMID:
20216313
35.

New directions in the systemic treatment of metastatic thyroid cancer.

Higgins MJ, Forastiere A, Marur S.

Oncology (Williston Park). 2009 Aug;23(9):768-75. Review.

36.

Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.

Vaishampayan UN, Marur S, Heilbrun LK, Cher ML, Dickow B, Smith DW, Al Hasan SA, Eliason J.

J Urol. 2009 Jul;182(1):317-23. doi: 10.1016/j.juro.2009.02.105. Epub 2009 May 17.

37.

Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.

Marur S, Eliason J, Heilbrun LK, Dickow B, Smith DW, Baranowski K, Alhasan S, Vaishampayan U.

Urology. 2008 Oct;72(4):898-902. doi: 10.1016/j.urology.2008.05.032. Epub 2008 Aug 9.

38.

Head and neck cancer: changing epidemiology, diagnosis, and treatment.

Marur S, Forastiere AA.

Mayo Clin Proc. 2008 Apr;83(4):489-501. doi: 10.4065/83.4.489. Review. Erratum in: Mayo Clin Proc. 2008 May;83(5):604.

PMID:
18380996

Supplemental Content

Support Center